Chinese Natural Remedy For Coronary Heart Disease Attracts MNC Interest
This article was originally published in PharmAsia News
The regenerative medicine laboratory jointly set up by the Chinese University of Hong Kong and Jinan University of Guangdong recently developed a natural remedy for treating coronary heart disease. Researchers say that the natural remedy, based on an edible Chinese herbal medicine usually consumed for headaches and urinary problems, has been tested on patients with coronary occlusion and late-stage coronary heart disease. Trial results show excellent therapeutic effects in the subjects from China, Hong Kong, Canada and the U.S. The lab plans to use the two active components extracted to develop five drugs, which are expected to launch in three years. Sources disclose that the remedy, whose intellectual property has been purchased by a Hong Kong businessman, is attracting the attention of many pharmaceutical MNCs. (Click here for more - Chinese Language)
You may also be interested in...
A flurry of financial appointments has been seen across the off-patent industry, involving major players Dr Reddy’s, Biocon, Mayne Pharma and Xbrane Biopharma.
Aurobindo has agreed to sell its US-based Natrol dietary supplements business at a significant premium to the $132.5m it paid in late 2014, as the Indian firm continues to drive into complex formulations in the US, including injectables and biosimilars.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.